Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Autifony Awarded £2.2 Million to Progress AUT00063 for Tinnitus into Phase IIa Study

Published: Wednesday, June 04, 2014
Last Updated: Wednesday, June 04, 2014
Bookmark and Share
Award follows successful completion of Phase I.

Autifony Therapeutics Limited has announced that it has been awarded funding of £2.2 million towards a Phase IIa clinical trial in tinnitus patients with its lead compound AUT00063, by the UK’s innovation agency, the Technology Strategy Board.

Autifony will be sponsor of the clinical study, with Professor Deborah Hall at The University of Nottingham and National Institute for Health Research (NIHR) Nottingham Hearing Biomedical Research Unit (BRU) as lead academic collaborator.

AUT00063 is a first-in-class Kv3 potassium channel modulator in development for the treatment of age-related hearing loss, for which a Phase IIa clinical trial is expected to start later this year. The Technology Strategy Board funding award will now enable Autifony to initiate a randomized, placebo controlled Phase IIa study in patients with tinnitus in the UK, allowing Autifony to test the drug’s efficacy in this poorly served patient group.

The award follows an application to the Biomedical Catalyst, jointly funded by the Technology Strategy Board and the Medical Research Council, and comes after the recent successful completion of a randomized, placebo controlled Phase I study, conducted in the UK, which investigated the safety, tolerability and pharmacokinetics of orally administered single and multiple dose regimens of AUT00063 in more than 60 young and elderly healthy volunteers.

In the study the drug appeared safe and well tolerated, and no serious adverse events were recorded. AUT00063 showed excellent pharmacokinetics, compatible with once/daily oral dosing.

The Phase I trial also explored a variety of novel pharmacodynamic endpoints and interactions, which confirmed the engagement of the drug with the Kv3 ion channel target, and provided further supporting evidence for dose selection in the Phase II studies.

Dr Charles Large, Chief Executive Officer of Autifony, commented: “There is a huge need for a drug to treat tinnitus, which is surprisingly common, affecting over 10% of the population. Tinnitus seriously impacts quality of life for up to 1% of people, disrupting sleep and concentration, as well as affecting their hearing and emotional state. We are very hopeful that our pioneering Kv3 channel modulator approach may be able to bring some relief to patients with tinnitus, although there is clearly still a long development path ahead of us. The Technology Strategy Board funding will be very helpful in enabling us to test AUT00063 in this additional indication with such high unmet medical need."

Dr Ralph Holme, Head of Biomedical Research at Action on Hearing Loss, the UK charity dedicated to hearing loss research, commented: “On a daily basis we are contacted by people who struggle to cope with their tinnitus and want to know if there are effective treatments for this condition. We are delighted that Autifony, who we have worked with closely from their inception, has secured funding to continue clinical testing on a potential new drug treatment that we hope will bring relief to tinnitus sufferers.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dr John Hutchison Joins Autifony Therapeutics as Chief Medical Officer
Dr Hutchison brings a wealth of experience of clinical drug development in both big pharma and the biotech sector.
Friday, September 04, 2015
Autifony Initiates Phase I Study for AUT00063 for Hearing Loss and Tinnitus Treatment
Company tops up Series A financing with further £5.5 million investment.
Monday, June 10, 2013
Scientific News
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!